Abstract:
The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.
Abstract:
In a cluster system comprising at least two nodes connected via a communication network and having a name and a host weight assigned to it, a method is implemented comprising the steps of inspecting the communication link, determining which node has to be shut down after a failure, creating an advertisement report for the node to be shut down, sending the advertisement report to at least one node of the cluster system, calculating a delay time depending on the weight of the first node and sending the shut down command to the node for which a failure report was received. In one embodiment of the invention the advertisement reports include a master node, which allows identifying and specifying the surviving subcluster. The method will send shut down signals to those nodes of a subcluster with lower weight than the surviving subcluster. A failsafe mechanism is implemented.
Abstract:
The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.
Abstract:
In order to provide necessary information for the production of complete human monoclonal antibodies capable of human CD152 (CTLA-4) binding, the primary structures of heavy and light chains have been elucidated. The novel amino acid sequence of identified heavy and light chains are derived from VH3 and Vλ germline genes, respectively. Antibodies comprising such novel structures cause specific binding to soluble recombinant human CD152 as well as to activated human peripheral T cells, where the expression of CD152 has been elevated.
Abstract:
A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
Abstract:
A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.
Abstract:
A light emitting decoration has a decoration unit having a colored and lighting decoration; the colored and lighting decoration being capable of refracting light as light passing therethrough; a light emitting unit having at least one transmission line which is bendable to be formed as a figure or characters; the transmission line being installed with a plurality of light emitting elements; the transmission line being wound and adhered to the colored and lighting decoration. The decoration has a ring which can be worn around a finger of a user. The light emitting unit has a control circuit board with predetermined control way; the control circuit board is installed with a battery as a power source and a switch key.
Abstract:
A pair of light emitting knickers comprises a pair of knickers having an edge strip; a light emitting unit being installed on the edge strip of the knickers through a combining unit; the light emitting unit including a flexible transmission line; the transmission line being bendable to be as characters or patterns on the edge strip; the transmission line being installed with a plurality of light emitting elements; a combining unit for combining the light emitting unit to the edge strip; wherein by the light emitting unit, the knickers can light up by actuating the light emitting elements of the light emitting unit. The light emitting unit has a control circuit board with a predetermined control way; and the control circuit board is installed with batteries and control switches. Moreover the light emitting unit can be used to a brassiere.
Abstract:
A computer arrangement for providing services to clients over a network includes: at least two servers, each server hosting at least one application, an automated administrator configured to automatically provision the servers to provide the services, and at least one network load balancer connected to the clients and the servers. The network load balancer is responsible for at least one of the services and is configured to gather state information on the state of the servers and/or the applications hosted on the servers and is operable to route incoming requests of clients to at least one of the servers. The network load balancer provides the automated administrator with the state information. The automated administrator provides the network load balancer with provisioning information regarding which servers are provisioned to provide the at least one service for which the network load balancer is responsible.
Abstract:
A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDRl, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.